Physician profile
Suzie T Nemmers
NPI 1780774331
$3,721.74
in general payments reported to CMS, 2019-2025
22 companies · $743 in 2025
The $743 reported for 2025 was more than what 86% of Pediatric Ophthalmology and Strabismus Specialist providers received nationally (typical 2025 total: $118).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,161 · 2021: $46.50 · 2022: $335 · 2023: $1,030 · 2024: $406 · 2025: $743.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,175 · Education: $3.19.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,175.35 |
| Education | $3.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $570.37 | 2019-2025 | Clareon, Unity, Wavelight Ex500 Excimer Laser |
| Sight Sciences, INC. | $389.76 | 2022-2025 | Omni Surgical System |
| Abbvie INC. | $336.81 | 2023 | |
| Genentech USA, INC. | $268.90 | 2019-2024 | Vabysmo |
| Dompe US, INC. | $246.82 | 2022-2025 | Oxervate |
| Regeneron Healthcare Solutions, INC. | $243.87 | 2023-2024 | Eylea Hd, Eylea |
| Johnson & Johnson Surgical Vision, INC. | $215.26 | 2019 | |
| Eyevance Pharmaceuticals LLC | $155.41 | 2019 | |
| Glaukos Corporation | $129.41 | 2023 | |
| Apellis Pharmaceuticals, INC. | $128.60 | 2025 | Syfovre |
| Novartis Pharmaceuticals Corporation | $125.00 | 2019 | |
| Harrow Eye, LLC | $124.72 | 2023 | Iheezo |
| Oyster Point Pharma, INC. | $120.82 | 2024 | Tyrvaya |
| Aerie Pharmaceuticals, INC. | $120.07 | 2019 | |
| Allergan, INC. | $115.59 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $114.97 | 2025 | Acthar |
| Mallinckrodt Enterprises LLC | $109.48 | 2019 | |
| Horizon Therapeutics Plc | $78.53 | 2023 | Tepezza |
| Staar Surgical Company | $56.00 | 2019 | |
| Carl Zeiss Meditec, INC. | $36.11 | 2023 | |
| Viiv Healthcare Company | $32.05 | 2023 | Apretude |
| Travere Therapeutics, INC. | $3.19 | 2023 | Cholbam |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzie Nemmers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.